Pfizer refers to three coronavirus vaccines that provide strong protection for children under the age of five.

Pfizer’s three doses Coronavirus Infectious Disease-19: Corona 19 The company announced Monday that the vaccine provides strong protection for children under five. Pfizer plans to provide data to US regulators later this week so that the youngest children can get injections.

The news comes after anxiously waiting months for parents desperate to vaccinate their babies, toddlers and preschoolers, especially as COVID-19 cases rise once again. Infants under 18 years of age are the only group in the United States not yet eligible for the COVID-19 vaccination.

The U.S. Food and Drug Administration (FDA) has begun evaluating data from competitor Moderna and hopes to begin offering two child-size injections by the summer.

Pfizer spent more time figuring out the approach. It aims to give children a lower dose (only a tenth of what an adult receives), but experiments found that two injections didn’t seem strong enough for preschoolers. So the researchers gave more than 1,600 young people between the ages of 6 months and 4 years a third shot during the winter surge of the omicron strain.

In a press release, Pfizer and partner BioNTech said that the additional injections were effective in raising levels of the virus-fighting antibody enough to meet FDA standards for emergency use of the vaccine without safety concerns.

Preliminary data shows that the 3-dose series is 80% effective in preventing symptomatic COVID-19, but it is noted that the calculations are based on 10 cases diagnosed among study participants by the end of April. Research rules require a minimum of 21 cases to be formally determined for validity, and Pfizer has promised to update as more data becomes available.

Both companies have already submitted data for the first and second doses to the FDA, and BioNTech’s CEO, Dr. Ugur Sahin said final third dose data will be submitted this week.

“Based on tolerability data, we suggest that our vaccine, at a low dose of 3 micrograms, carefully selected based on tolerability data suggests that our vaccine provides a high level of protection against the latest strain of COVID-19 in young children,” he said in a statement.

What future plans? FDA Vaccine Director Dr. Peter Marks promised that the FDA would move “quickly without sacrificing our standards” when evaluating the maximum doses of Pfizer and Moderna.

The agency has set a tentative date next month for scientific advisors to publicly discuss each company’s data.

modern Vaccinate young children first.. It submitted data to the FDA that babies develop high levels of virus-fighting antibodies after two injections that contain a quarter of the dose given to adults. A Moderna study found that during an omicron surge, the effectiveness against symptomatic COVID-19 was 40% to 50%, very similar to that of adults who received only two doses of the vaccine.

Complicating Moderna’s progress, the FDA has so far only allowed the vaccine to be used in adults.

The FDA is expected to review Moderna’s data on studies of the youngest age group and teens and elementary school students. Other countries have already expanded Moderna’s injections to children under 6 years of age.

Although COVID-19 is not usually as dangerous to children as adults, some children become severely ill or even die. And the Omicron variant has been particularly hard on children. Children under 5 years of age were hospitalized at a higher rate than the peak of the previous delta surge.

It’s not clear how much demand there will be to vaccinate the youngest. Pfizer Injections for Children 5-11 Years Old Although it opened in November, only about 30% of that age group received the recommended initial two doses. Last week, U.S. health officials said that for the best protection against the latest strain of coronavirus, elementary school-age children, like everyone over the age of 12, should receive additional shots.


Leave a Comment